Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $28.61 billion. The enterprise value is $30.42 billion.
| Market Cap | 28.61B |
| Enterprise Value | 30.42B |
Important Dates
The last earnings date was Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 147.64 million shares outstanding. The number of shares has increased by 1.01% in one year.
| Current Share Class | 147.64M |
| Shares Outstanding | 147.64M |
| Shares Change (YoY) | +1.01% |
| Shares Change (QoQ) | +1.16% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 94.14% |
| Float | 147.18M |
Valuation Ratios
The trailing PE ratio is 20.84 and the forward PE ratio is 14.34. Biogen's PEG ratio is 6.45.
| PE Ratio | 20.84 |
| Forward PE | 14.34 |
| PS Ratio | 2.88 |
| Forward PS | 2.88 |
| PB Ratio | 1.53 |
| P/TBV Ratio | 9.20 |
| P/FCF Ratio | 11.81 |
| P/OCF Ratio | 11.04 |
| PEG Ratio | 6.45 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.65, with an EV/FCF ratio of 12.56.
| EV / Earnings | 22.17 |
| EV / Sales | 3.06 |
| EV / EBITDA | 8.65 |
| EV / EBIT | 11.21 |
| EV / FCF | 12.56 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.35.
| Current Ratio | 3.06 |
| Quick Ratio | 2.03 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 1.80 |
| Debt / FCF | 2.71 |
| Interest Coverage | 9.87 |
Financial Efficiency
Return on equity (ROE) is 7.70% and return on invested capital (ROIC) is 10.92%.
| Return on Equity (ROE) | 7.70% |
| Return on Assets (ROA) | 5.90% |
| Return on Invested Capital (ROIC) | 10.92% |
| Return on Capital Employed (ROCE) | 10.25% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $182,920 |
| Employee Count | 7,500 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.00 |
Taxes
In the past 12 months, Biogen has paid $251.10 million in taxes.
| Income Tax | 251.10M |
| Effective Tax Rate | 15.47% |
Stock Price Statistics
The stock price has increased by +52.78% in the last 52 weeks. The beta is 0.19, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +52.78% |
| 50-Day Moving Average | 185.72 |
| 200-Day Moving Average | 169.22 |
| Relative Strength Index (RSI) | 54.59 |
| Average Volume (20 Days) | 1,215,226 |
Short Selling Information
The latest short interest is 4.48 million, so 3.03% of the outstanding shares have been sold short.
| Short Interest | 4.48M |
| Short Previous Month | 4.41M |
| Short % of Shares Out | 3.03% |
| Short % of Float | 3.04% |
| Short Ratio (days to cover) | 3.21 |
Income Statement
In the last 12 months, Biogen had revenue of $9.94 billion and earned $1.37 billion in profits. Earnings per share was $9.30.
| Revenue | 9.94B |
| Gross Profit | 7.82B |
| Operating Income | 2.71B |
| Pretax Income | 1.62B |
| Net Income | 1.37B |
| EBITDA | 3.52B |
| EBIT | 2.71B |
| Earnings Per Share (EPS) | $9.30 |
Balance Sheet
The company has $4.28 billion in cash and $6.56 billion in debt, with a net cash position of -$1.81 billion or -$12.28 per share.
| Cash & Cash Equivalents | 4.28B |
| Total Debt | 6.56B |
| Net Cash | -1.81B |
| Net Cash Per Share | -$12.28 |
| Equity (Book Value) | 18.65B |
| Book Value Per Share | 126.37 |
| Working Capital | 6.19B |
Cash Flow
In the last 12 months, operating cash flow was $2.59 billion and capital expenditures -$167.90 million, giving a free cash flow of $2.42 billion.
| Operating Cash Flow | 2.59B |
| Capital Expenditures | -167.90M |
| Depreciation & Amortization | 801.10M |
| Net Borrowing | -296.90M |
| Free Cash Flow | 2.42B |
| FCF Per Share | $16.41 |
Margins
Gross margin is 78.72%, with operating and profit margins of 27.32% and 13.81%.
| Gross Margin | 78.72% |
| Operating Margin | 27.32% |
| Pretax Margin | 16.33% |
| Profit Margin | 13.81% |
| EBITDA Margin | 35.38% |
| EBIT Margin | 27.32% |
| FCF Margin | 24.38% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.01% |
| Shareholder Yield | -1.01% |
| Earnings Yield | 4.80% |
| FCF Yield | 8.47% |
Analyst Forecast
The average price target for Biogen is $219.27, which is 13.17% higher than the current price. The consensus rating is "Buy".
| Price Target | $219.27 |
| Price Target Difference | 13.17% |
| Analyst Consensus | Buy |
| Analyst Count | 36 |
| Revenue Growth Forecast (5Y) | -0.31% |
| EPS Growth Forecast (5Y) | 9.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.12 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.12 |
| Piotroski F-Score | 6 |